Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Go back to Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide| Pfizer Inc. (NYSE: PFE) | Delayed: 24.86 -0.22 (0.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $24.99 | 52 Week Low | $28.25 | |||
| Day High | $25.24 | P/E | 15.07 | |||
| Day Low | $24.78 | EPS | $1.65 | |||
| Volume | 24,284,394 | |||||
